BioCentury | Aug 4, 2017
Clinical News

VBI's CMV vaccine induces 100% seroconversion in Phase I

...Phase I trial in 128 cytomegalovirus (CMV)-negative healthy volunteers showing that 2 μg intramuscular VBI-1501A (CMV eVLP...
...epithelial cell infection were reported in 17% of subjects receiving the highest dose of VBI-1501A. VBI-1501A...
...VBI’s enveloped virus-like particle (eVLP) platform. VBI Vaccines Inc. (NASDAQ:VBIV; TSX:VBV), Cambridge, Mass. Product: CMV eVLP (VBI-1501A...
BioCentury | Oct 3, 2016
Clinical News

CMV eVLP: Completed Phase I enrollment

...in a placebo-controlled, Canadian Phase I trial evaluating unadjuvanted VBI-1501A and 3 doses of adjuvanted VBI-1501A...
...months 0, 2 and 6. VBI Vaccines Inc. (NASDAQ:VBIV; TSX:VBV), Cambridge, Mass. Product: CMV eVLP ( VBI-1501A...
BioCentury | Sep 5, 2016
Clinical News

CMV eVLP: Phase I ongoing

...of a placebo-controlled, Canadian Phase I trial evaluating unadjuvanted VBI-1501A and 3 doses of adjuvanted VBI-1501A...
...about 125 CMV-seronegative healthy volunteers. VBI Vaccines Inc. (NASDAQ:VBIV; TSX:VBV), Cambridge, Mass. Product: CMV eVLP ( VBI-1501A...
BioCentury | Jul 11, 2016
Clinical News

CMV eVLP: Phase I started

...a placebo-controlled, Canadian Phase I trial to evaluate unadjuvanted VBI-1501A and 3 doses of adjuvanted VBI-1501A...
...125 CMV-seronegative healthy adult volunteers. VBI Vaccines Inc. (NASDAQ:VBIV; TSX:VBV), Cambridge, Mass. Product: CMV eVLP ( VBI-1501A...
BioCentury | Dec 7, 2015
Company News

VBI Vaccines, SciVac deal

...by the combined company. The deal is expected to close in 1Q16. VBI is developing VBI-1501A...
Items per page:
1 - 5 of 5